These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


296 related items for PubMed ID: 12010863

  • 1. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M, Albert Einstein Cervix Dysplasia Clinical Consortium.
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [Abstract] [Full Text] [Related]

  • 2. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH.
    J Natl Cancer Inst; 1997 Sep 03; 89(17):1285-93. PubMed ID: 9293919
    [Abstract] [Full Text] [Related]

  • 3. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK, Tortolero-Luna G, Follen M, Sastry KJ.
    Gynecol Oncol; 2005 Dec 03; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [Abstract] [Full Text] [Related]

  • 4. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y, Choi JW, Kim HJ, Eddouzi J, Kim SC, Ju W, Kim YH, Kim HJ.
    Cancer Med; 2018 Nov 03; 7(11):5655-5664. PubMed ID: 30353680
    [Abstract] [Full Text] [Related]

  • 5. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A, Koskimaa HM, Welters MJ, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.
    J Transl Med; 2015 May 20; 13():163. PubMed ID: 25990808
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S, Simon P, Maudoux F, Doyen J, Noël JC, Beliard A, Capelle X, Buxant F, Fayt I, Lagrost AC, Hubert P, Gerday C, Burny A, Boniver J, Foidart JM, Delvenne P, Jacobs N.
    Cancer Immunol Immunother; 2004 Jul 20; 53(7):642-50. PubMed ID: 14985860
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, Moscicki AB, Palefsky JM.
    J Infect Dis; 1997 Apr 20; 175(4):927-31. PubMed ID: 9086151
    [Abstract] [Full Text] [Related]

  • 8. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
    Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, Walboomers JM.
    Int J Cancer; 2000 Oct 01; 88(1):92-8. PubMed ID: 10962445
    [Abstract] [Full Text] [Related]

  • 9. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ.
    J Gen Virol; 1996 Sep 01; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [Abstract] [Full Text] [Related]

  • 10. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.
    Höpfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Müller-Holzner E, Pawlita M, Pfister H, Fritsch P.
    Lancet; 2000 Dec 09; 356(9246):1985-6. PubMed ID: 11130532
    [Abstract] [Full Text] [Related]

  • 11. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M, Hirohashi Y, Torigoe T, Kuroda T, Yasuda K, Shimizu Y, Saito T, Sato N.
    Exp Mol Pathol; 2012 Feb 09; 92(1):185-90. PubMed ID: 22032938
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.
    Luxton JC, Nath R, Derias N, Herbert A, Shepherd PS.
    J Gen Virol; 2003 May 09; 84(Pt 5):1063-1070. PubMed ID: 12692269
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
    Nindl I, Rindfleisch K, Lotz B, Schneider A, Dürst M.
    Int J Cancer; 1999 Jul 19; 82(2):203-7. PubMed ID: 10389753
    [Abstract] [Full Text] [Related]

  • 19. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.
    Kadish AS, Romney SL, Ledwidge R, Tindle R, Fernando GJ, Zee SY, Van Ranst MA, Burk RD.
    J Gen Virol; 1994 Sep 19; 75 ( Pt 9)():2277-84. PubMed ID: 8077925
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.